Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) had its price objective boosted by equities researchers at Guggenheim from $97.00 to $106.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Guggenheim's price target points to a potential upside of 28.72% from the stock's current price.
A number of other research analysts have also recently commented on SLNO. HC Wainwright reissued a "buy" rating and issued a $100.00 target price on shares of Soleno Therapeutics in a report on Tuesday, April 15th. Piper Sandler increased their target price on shares of Soleno Therapeutics from $93.00 to $145.00 and gave the stock an "overweight" rating in a report on Thursday, April 24th. Oppenheimer increased their target price on shares of Soleno Therapeutics from $105.00 to $110.00 and gave the stock an "outperform" rating in a report on Thursday. Cowen initiated coverage on shares of Soleno Therapeutics in a report on Monday, June 23rd. They issued a "buy" rating for the company. Finally, TD Cowen initiated coverage on shares of Soleno Therapeutics in a report on Monday, June 23rd. They issued a "buy" rating and a $110.00 target price for the company. One research analyst has rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Soleno Therapeutics presently has an average rating of "Buy" and a consensus target price of $113.30.
Get Our Latest Analysis on Soleno Therapeutics
Soleno Therapeutics Price Performance
Soleno Therapeutics stock traded up $3.64 during trading hours on Thursday, reaching $82.35. 1,068,500 shares of the stock were exchanged, compared to its average volume of 1,254,333. The company has a market cap of $4.38 billion, a P/E ratio of -19.89 and a beta of -2.56. The company has a current ratio of 15.13, a quick ratio of 19.64 and a debt-to-equity ratio of 0.21. Soleno Therapeutics has a twelve month low of $41.50 and a twelve month high of $90.32. The stock has a 50 day moving average of $82.66 and a two-hundred day moving average of $68.21.
Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.53) by $0.44. The firm had revenue of $32.66 million for the quarter, compared to analyst estimates of $3.91 million. Equities analysts expect that Soleno Therapeutics will post -3.72 EPS for the current fiscal year.
Insider Transactions at Soleno Therapeutics
In related news, insider Patricia C. Hirano sold 3,830 shares of the firm's stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $82.76, for a total value of $316,970.80. Following the completion of the transaction, the insider owned 13,206 shares in the company, valued at $1,092,928.56. This trade represents a 22.48% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 6.40% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Soleno Therapeutics by 1.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,360 shares of the company's stock worth $1,242,000 after purchasing an additional 189 shares during the last quarter. Moody Aldrich Partners LLC raised its holdings in Soleno Therapeutics by 0.7% during the 1st quarter. Moody Aldrich Partners LLC now owns 29,810 shares of the company's stock worth $2,130,000 after purchasing an additional 196 shares during the last quarter. Avanza Fonder AB raised its holdings in Soleno Therapeutics by 14.8% during the 1st quarter. Avanza Fonder AB now owns 1,951 shares of the company's stock worth $144,000 after purchasing an additional 251 shares during the last quarter. AlphaQuest LLC raised its holdings in Soleno Therapeutics by 37.5% during the 1st quarter. AlphaQuest LLC now owns 983 shares of the company's stock worth $70,000 after purchasing an additional 268 shares during the last quarter. Finally, SG Americas Securities LLC raised its holdings in Soleno Therapeutics by 8.6% during the 1st quarter. SG Americas Securities LLC now owns 4,397 shares of the company's stock worth $314,000 after purchasing an additional 350 shares during the last quarter. Institutional investors own 97.42% of the company's stock.
About Soleno Therapeutics
(
Get Free Report)
Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.
Further Reading
Before you consider Soleno Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Soleno Therapeutics wasn't on the list.
While Soleno Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
